FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480808169> ?p ?o ?g. }

• W2480808169 endingPage "427" @default.
• W2480808169 startingPage "421" @default.
• W2480808169 abstract "Background Analyses of associations between clinicopathologic outcomes and recurrent somatic mutations in clear cell renal cell carcinoma (ccRCC) have been limited to individual cohorts. Objective To define clinicopathologic associations between specific mutations and ccRCC disease characteristics. Design, setting, and participants DNA sequencing data were pooled from three collaborative genomic cohorts (n = 754) and our institutional database (n = 295). All patients had clinical data and identification of somatic mutations from their primary tumors. Outcome measurements and statistical analysis Analysis of gene mutations for associations with maximal tumor size (linear regression) and pathologic stage (logistic regression). Cancer-specific survival (CSS) and recurrence-free survival (RFS) were calculated using competing risks methods. Analyses were adjusted for cohort site, and results were adjusted for multiple testing (q value). Relevant genes were used in multivariable models that included confounding variables and the validated Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) score. Results and limitations Association with tumor size was found for mutations in BAP1 (q = 0.013). No mutations were found to be associated with stage after adjusted analysis. Mutations in BAP1 (q = 0.004) and TP53 (q = 0.001) were associated with decreased CSS in a multivariable model; only TP53 (q = 0.005) remained significant when SSIGN score was included. SETD2 mutations (q = 0.047) were associated with decreased RFS in multivariable models, including models with SSIGN score. Conclusions In >1000 patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three mutated genes have statistically significant associations with poor clinical outcomes. This included the more commonly mutated BAP1 and SETD2 and the less frequently mutated TP53. After adjustment for clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively. Patient summary Using rigorous statistical methods, this study affirmed that certain mutations in clear cell renal cell carcinoma may portend inferior survival and an increased risk of recurrence." @default.
• W2480808169 created "2016-08-23" @default.
• W2480808169 creator A5002190570 @default.
• W2480808169 creator A5004624794 @default.
• W2480808169 creator A5005708651 @default.
• W2480808169 creator A5010536553 @default.
• W2480808169 creator A5018531384 @default.
• W2480808169 creator A5018611273 @default.
• W2480808169 creator A5021734597 @default.
• W2480808169 creator A5022741402 @default.
• W2480808169 creator A5029942527 @default.
• W2480808169 creator A5030709443 @default.
• W2480808169 creator A5042588749 @default.
• W2480808169 creator A5053263729 @default.
• W2480808169 creator A5053547168 @default.
• W2480808169 creator A5058812626 @default.
• W2480808169 creator A5059063118 @default.
• W2480808169 creator A5063705438 @default.
• W2480808169 creator A5070428340 @default.
• W2480808169 creator A5071062016 @default.
• W2480808169 creator A5075829688 @default.
• W2480808169 creator A5081581200 @default.
• W2480808169 creator A5089094298 @default.
• W2480808169 creator A5091859782 @default.
• W2480808169 date "2017-10-01" @default.
• W2480808169 modified "2023-10-17" @default.
• W2480808169 title "Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma" @default.
• W2480808169 cites W1520140649 @default.
• W2480808169 cites W1524165063 @default.
• W2480808169 cites W1968657935 @default.
• W2480808169 cites W1983986272 @default.
• W2480808169 cites W1986302429 @default.
• W2480808169 cites W1992142098 @default.
• W2480808169 cites W2019756490 @default.
• W2480808169 cites W2079212177 @default.
• W2480808169 cites W2092892924 @default.
• W2480808169 cites W2093103292 @default.
• W2480808169 cites W2095698093 @default.
• W2480808169 cites W2096172976 @default.
• W2480808169 cites W2106915273 @default.
• W2480808169 cites W2122018421 @default.
• W2480808169 cites W2144171381 @default.
• W2480808169 cites W2148287035 @default.
• W2480808169 cites W2148424438 @default.
• W2480808169 cites W2152162065 @default.
• W2480808169 cites W2152874907 @default.
• W2480808169 cites W2158290434 @default.
• W2480808169 cites W223909586 @default.
• W2480808169 cites W2270637060 @default.
• W2480808169 cites W2335012284 @default.
• W2480808169 cites W2591351015 @default.
• W2480808169 doi "https://doi.org/10.1016/j.euf.2016.06.015" @default.
• W2480808169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5650556" @default.
• W2480808169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28753773" @default.
• W2480808169 hasPublicationYear "2017" @default.
• W2480808169 type Work @default.
• W2480808169 sameAs 2480808169 @default.
• W2480808169 citedByCount "36" @default.
• W2480808169 countsByYear W24808081692017 @default.
• W2480808169 countsByYear W24808081692018 @default.
• W2480808169 countsByYear W24808081692019 @default.
• W2480808169 countsByYear W24808081692020 @default.
• W2480808169 countsByYear W24808081692021 @default.
• W2480808169 countsByYear W24808081692022 @default.
• W2480808169 countsByYear W24808081692023 @default.
• W2480808169 crossrefType "journal-article" @default.
• W2480808169 hasAuthorship W2480808169A5002190570 @default.
• W2480808169 hasAuthorship W2480808169A5004624794 @default.
• W2480808169 hasAuthorship W2480808169A5005708651 @default.
• W2480808169 hasAuthorship W2480808169A5010536553 @default.
• W2480808169 hasAuthorship W2480808169A5018531384 @default.
• W2480808169 hasAuthorship W2480808169A5018611273 @default.
• W2480808169 hasAuthorship W2480808169A5021734597 @default.
• W2480808169 hasAuthorship W2480808169A5022741402 @default.
• W2480808169 hasAuthorship W2480808169A5029942527 @default.
• W2480808169 hasAuthorship W2480808169A5030709443 @default.
• W2480808169 hasAuthorship W2480808169A5042588749 @default.
• W2480808169 hasAuthorship W2480808169A5053263729 @default.
• W2480808169 hasAuthorship W2480808169A5053547168 @default.
• W2480808169 hasAuthorship W2480808169A5058812626 @default.
• W2480808169 hasAuthorship W2480808169A5059063118 @default.
• W2480808169 hasAuthorship W2480808169A5063705438 @default.
• W2480808169 hasAuthorship W2480808169A5070428340 @default.
• W2480808169 hasAuthorship W2480808169A5071062016 @default.
• W2480808169 hasAuthorship W2480808169A5075829688 @default.
• W2480808169 hasAuthorship W2480808169A5081581200 @default.
• W2480808169 hasAuthorship W2480808169A5089094298 @default.
• W2480808169 hasAuthorship W2480808169A5091859782 @default.
• W2480808169 hasBestOaLocation W24808081692 @default.
• W2480808169 hasConcept C121608353 @default.
• W2480808169 hasConcept C126322002 @default.
• W2480808169 hasConcept C143998085 @default.
• W2480808169 hasConcept C151956035 @default.
• W2480808169 hasConcept C2777472916 @default.
• W2480808169 hasConcept C2781278892 @default.
• W2480808169 hasConcept C37846818 @default.
• W2480808169 hasConcept C50382708 @default.
• W2480808169 hasConcept C71924100 @default.

• next